Table 1. Clinical and pulmonary function primary baseline parameters.
| Control | AP1 | AP2 | P | ||
|---|---|---|---|---|---|
| N | 6 | 6 | 7 | ||
| Age | 23.3 (4.1) | 22.2 (3.7) | 20.1 (2.0) | 0.298 | |
| Male/Female | 4/2 | 2/4 | 4/3 | 0.489 * | |
| BMI | 0.251 * | ||||
| <18.5 | 0.00 (0) | 0.00 (0) | 0.00 (0) | ||
| 18.5–24.9 | 66.7 (4) | 33.3 (2) | 71.4 (5) | ||
| 25.0–29.9 | 33.3 (2) | 16.7 (1) | 14.3 (1) | ||
| ≥ 30.0 | 0.00 (0) | 50.0 (3) | 14.3 (1) | ||
| FEV1 (L) | 3.9 (0.5) | 3.5 (0.4) | 3.1 (0.5) | 0.063 | |
| FEV1 (% predicted) | 94.6 (7.9) | 89.8 (8.5) | 76.4 (8.1) | 0.006 | |
| FVC (L) | 4.7 (0.6) | 4.5 (0.7) | 4.3 (0.9) | 0.738 | |
| FEV1/FVC | 0.82 (0.05) | 0.79 (0.10) | 0.73 (0.07) | 0.129 | |
| Obstruction FEV1/FVC < LLN | 0.042 * | ||||
| Normal | 66.7 (4) | 14.2 (1) | |||
| Mild | 33.3 (2) | 42.9 (3) | |||
| Moderate | 0.00 (0) | 42.9 (3) | |||
| PD15+ | 0.00 (0) | 100.0 (6) | 100.0 (7) | <0.001 * | |
| PD15 (mg) | 255(112–580) | 73 (40–134) | 0.012 | ||
| ACQ Score | 0.521 * | ||||
| <0.75 | 50.0 (3) | 33.3 (2) | |||
| 0.75–1.5 | 16.7 (1) | 16.7 (1) | |||
| >1.5 | 33.3 (2) | 50.0 (3) | |||
| Bronchodilator Response | 0.758 * | ||||
| ΔFEV1 (L) < 0.2 L | 83.3 (5) | 66.7 (4) | 66.7 (4) | ||
| ΔFEV1 (L) > 0.2 L | 16.7 (1) | 33.3 (2) | 33.3 (2) | ||
| SPT+ | 50.0 (3) | 100.0 (6) | 100.0 (7) | 0.021 * |
Continuous variables reported as mean (standard deviation) and categorical variable reported as percentage (N). Asthma phenotype (AP) 1 and 2, body mass index (BMI), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and lower limit of normal as determined by ATS/ERS guidelines 5] (LLN), positive mannitol bronchial provocation test (PD15 +), provocation dose mannitol bronchial provocation test (PD15), asthma control questionnaire (ACQ), positive skin prick test (SPT+).
* Significance determined by Chi-square analysis with boot-strap approximation of distribution